No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy

Author(s):

Talia M. Mota, Thomas A. Rasmussen, Ajantha Rhodes, Surekha Tennakoon, Ashanti Dantanarayana, Fiona Wightman, Michelle Hagenauer, Janine Roney, Tim Spelman, Damian F.J. Purcell, James McMahon, Jennifer F. Hoy, H. Miles Prince, Julian H. Elliott, Sharon R. Lewin

Details:

AIDS, Volume 31, Issue 8, 2017-05-15

Article Link: Click here

Affiliations:

• University of Melbourne
• Monash University
• Aarhus Universitetshospital
• Peter Maccallum Cancer Centre
• Department of Microbiology & Immunology
• Burnet Institute